Drug Type Diagnostic radiopharmaceuticals, Radionuclide Drug Conjugates (RDC) |
Synonyms HBED-CC-PHENOXY-PSMA, 68GA-P16-093, GA-68 P16-093 + [5] |
Target |
Action inhibitors |
Mechanism PSMA inhibitors(Prostate-specific membrane antigen inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenocarcinoma of prostate | Phase 3 | China | 01 Oct 2020 | |
Primary Sjögren's syndrome | Phase 2 | - | 01 Oct 2023 | |
Glioblastoma | Phase 2 | China | 28 Nov 2021 | |
High grade glioma | Phase 2 | China | 28 Nov 2021 | |
Non-metastatic prostate cancer | Phase 2 | United States | 10 May 2018 | |
Metastatic Prostate Carcinoma | Phase 1 | United States | 21 Jul 2017 | |
PSMA-Positive Tumor | Phase 1 | United States | 21 Jul 2017 | |
Renal Cell Carcinoma | Phase 1 | United States | 21 Jul 2017 |
Not Applicable | - | 18 F-fluciclovine PET/CT | nqqwqkmyvv(qbiwfiminv) = qdorlefclw grfsfnzdgn (xofdlzcqhp ) | - | 24 Sep 2021 | ||
Not Applicable | - | 68 Ga]Ga-P16-093 (PSMA-targeted PET with [68Ga]Ga-P16-093) | sdiwzkmxrp(fhlfpwwaag) = efwjhdkjcx hcjsqkrosg (jjzuctuuoj ) | - | 15 May 2020 |